Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.

Gottlieb A, Canbay A.

Cells. 2019 Oct 30;8(11). pii: E1358. doi: 10.3390/cells8111358. Review.

2.

Implications of Immunotherapy in Hepatobiliary Tumors.

Gottlieb A, Best J, Canbay A.

Visc Med. 2019 Mar;35(1):18-26. doi: 10.1159/000496755. Epub 2019 Feb 8. Review.

PMID:
31312646
3.

Single-Center Retrospective Study of Clinical and Laboratory Features That Predict Survival of Patients With Budd-Chiari Syndrome After Liver Transplant.

Jeschke B, Gottlieb A, Sowa JP, Jeschke S, Treckmann JW, Gerken G, Canbay A.

Exp Clin Transplant. 2019 Oct;17(5):665-672. doi: 10.6002/ect.2018.0274. Epub 2019 May 2.

4.

Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.

Gottlieb A, Mosthael W, Sowa JP, Canbay A.

Digestion. 2019;100(2):79-85. doi: 10.1159/000493259. Epub 2018 Dec 7. Review.

5.

How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.

Gottlieb A, Kottmann M, Manka P, Bedreli S, Hadem J, Bechmann L, Sowa JP, Gerken G, Canbay A.

Dig Dis. 2019;37(2):147-154. doi: 10.1159/000492869. Epub 2018 Sep 18.

PMID:
30227404
6.

The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids.

Gottlieb A, Bechmann L, Canbay A.

Ann Hepatol. 2018 May-June;17(3):340-341. doi: 10.5604/01.3001.0011.7378. Epub 2018 Apr 9.

7.

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, K√ľnkele A.

Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840.

Supplemental Content

Loading ...
Support Center